Tax add-back targets pharma marketing expenses

Summary#

SF-5290 would amend Minnesota’s individual income tax and corporate franchise tax laws. It would require taxpayers to add back certain direct-to-consumer pharmaceutical marketing expenses when calculating Minnesota taxable income, even if they deducted those expenses under federal tax law. The bill does not state a goal beyond requiring this tax adjustment; it is introduced and has not become law.

  • The add-back would cover qualifying advertising and promotional activities directed at US consumers to promote a prescription drug or biologic.
  • The definition includes television, radio, print, digital and social media advertising, plus some patient outreach and disease-awareness campaigns funded by a pharmaceutical manufacturer and linked to a specific product.
  • If enacted, the change would apply to taxable years beginning after December 31, 2026.
  • The bill does not ban marketing or prevent a federal tax deduction; it changes how the specified deduction is treated for Minnesota tax calculations.

What it means for you#

  • Taxpayers: A person or business claiming a federal deduction for covered marketing expenses would have to add that amount to income for the relevant Minnesota tax calculation. The bill does not say how the adjustment would affect any particular taxpayer’s final tax bill.
  • Pharmaceutical businesses: Those with covered marketing expenses could face a higher Minnesota taxable-income calculation. The bill does not require them to stop advertising.
  • Other Minnesotans: The bill does not directly change drug prices, prescriptions, insurance coverage, or access to medicines.

Money#

No estimate of state revenue or administration costs is provided. No publicly available information.

  • The bill requires a tax add-back, but does not estimate how much additional state revenue it might produce.
  • It does not set a fee, fine, or spending program.

What is unclear#

  • The supplied material does not include the current text of the amended statutes, so it is not possible to verify how this change would interact with existing Minnesota tax rules.
  • The bill does not explain how taxpayers should identify, document, or allocate marketing expenses that include both covered and other activities.
  • It defines “pharmaceutical manufacturer,” but does not clearly state which taxpayers, beyond those claiming the deduction, would have to make the add-back.
  • The bill does not provide a revenue estimate or explain how the change would be administered.

Case for#

  • A possible argument for the bill is that covered marketing expenses would no longer reduce Minnesota taxable income when they are deducted under federal law.
  • This could make Minnesota’s tax treatment of these expenses different from the federal treatment, while leaving federal deductions unchanged.
  • The bill sets out examples of covered marketing, which could help identify some expenses that would be added back.

Case against#

  • The add-back could increase Minnesota tax liability for taxpayers with covered deductions, but the bill gives no estimate of how many taxpayers or how much revenue would be affected.
  • It is unclear how to treat mixed campaigns or expenses that are difficult to link to a specific product.
  • The bill does not explain why this category of marketing expenses should receive different state tax treatment from other deductible business expenses.